Prevalence of immune‑related adverse events and anti‑tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

免疫チェックポイント阻害薬を使用した悪性腫瘍患者における免疫関連有害事象の頻度と病態

Yoshikawa Yuki

eng

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

BMC Cancer (2022) 22:1232

[DOI] https://doi.org/10.1186/s12885-022-10327-7

広島大学

Hiroshima University